On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

This study tests the safety, tolerability, and effectiveness of a new CAR-T cell therapy called UTAA09 in patients with different types of B-cell lymphoma that have relapsed or stopped responding to standard treatments, where the cancer cells are positive for CD19 and/or CD20. **You may be eligible if...** - You have confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or indolent lymphoma that has transformed to a more aggressive form - Your cancer tests positive for CD19 and/or CD20 - You have at least one measurable tumor - Your overall health is good (ECOG score 0–1) **You may NOT be eligible if...** - You have previously received CAR-T therapy or other gene-modified cell therapies - You are on long-term systemic steroid therapy - You have significant heart disease (recent heart attack within 6 months, unstable angina, severe heart failure, or serious arrhythmia) Talk to your doctor to see if this trial is right for you.